A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays

Journal of Immunological Methods

Volumn 426, Issue , 2015, Pages 62-69

  Zoghbi, Jad ^a   Xu, Yuanxin ^a   Grabert, Ryan ^a   Theobald, Valerie ^a   Richards, Susan ^a  

^a SANOFI   (France)

Author keywords

ADA; Anti drug antibody; Drug interference; Drug tolerance; Immunoassay; Immunogenicity; Ligand binding assays; Targetinterference

Indexed keywords

BIOLOGICAL MARKER; DRUG ANTIBODY; MONOCLONAL ANTIBODY; ANTIGEN ANTIBODY COMPLEX; ANTIIDIOTYPIC ANTIBODY; DRUG;

ACID DISSOCIATION CONSTANT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DIMERIZATION; DOSE RESPONSE; DRUG COMPETITION; DRUG HALF LIFE; DRUG TOLERANCE; FALSE POSITIVE RESULT; IMMUNOASSAY; IMMUNOGENICITY; LIMIT OF QUANTITATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; BLOOD; EVALUATION STUDY; HUMAN; IMMUNOLOGY; PRECIPITATION;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY FORMATION; ANTIGEN-ANTIBODY COMPLEX; BIOMARKERS; CHEMICAL PRECIPITATION; DRUG TOLERANCE; HUMANS; IMMUNOASSAY; PHARMACEUTICAL PREPARATIONS;

EID: 84949314715     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2015.08.002     Document Type: Article

References (14)

1. Koren E., Zuckerman L.A., Mire-Sluis A.R. Immune responses to therapeutic proteins in humans - Clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 2002, 3(4):349.
2. Ohlson S., Zetterstrand K. Detection of circulating immune complexes by PEG precipitation combined with ELISA. J. Immunol. Methods 1985, 77(1):87.
3. Koren E., Smith H.W., Shores E., et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 2008, 333(1-2):1.
4. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 2004, 289(1-2):1.
5. Shankar G., Devanarayan V., Amaravadi L., et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008, 48(5):1267.
6. Porter S. Human immune response to recombinant human proteins. J. Pharm. Sci. 2001, 90(1):1.
7. Moxness M., Tatarewicz S., Weeraratne D., et al. Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin. Chem. 2005, 51(10):1983.
8. Patton A., Mullenix M.C., Swanson S.J., Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J. Immunol. Methods 2005, 304(1-2):189.
9. Smith H.W., Butterfield A., Sun D. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regul. Toxicol. Pharmacol. 2007, 49(3):230.
10. Bourdage J.S., Cook C.A., Farrington D.L., Chain J.S., Konrad R.J. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J. Immunol. Methods 2007, 327(1-2):10.
11. Crisino R.M., Luo L., Geist B., Zoghbi J., Spriggs F. Matrix effect in ligand-binding assay: the importance of evaluating emerging technologies. Bioanalysis 2014, 6(8):1033.
12. Creighton W.D., Lambert P.H., Miescher P.A. Detection of antibodies and soluble antigen antibody complexes by precipitation with polyethylene glycol. J. Immunol. 1973, 111(4):1219.
13. Moxness M., Foley J., Stene M., et al. Development and validation of radioligand binding assays to measure total, IgA, IgE, IgG, and IgM insulin antibodies in human serum. Ann. N. Y. Acad. Sci. 2003, 1005:265.
14. Dai S., Schantz A., Clements-Egan A., Cannon M., Shankar G. Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity. AAPS J. 2014, 16(3):464.